Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine
Introduction: Malaria is a devastating vector-borne disease caused by the Plasmodium parasite, resulting in almost 0.5 million casualties per year. The parasite has a complex life-cycle that includes asexual replication in human red blood cells, causing symptomatic malaria, and sexual stages which a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-04-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2017.1276833 |
| _version_ | 1827813212481912832 |
|---|---|
| author | Michael Theisen Matthijs M. Jore Robert Sauerwein |
| author_facet | Michael Theisen Matthijs M. Jore Robert Sauerwein |
| author_sort | Michael Theisen |
| collection | DOAJ |
| description | Introduction: Malaria is a devastating vector-borne disease caused by the Plasmodium parasite, resulting in almost 0.5 million casualties per year. The parasite has a complex life-cycle that includes asexual replication in human red blood cells, causing symptomatic malaria, and sexual stages which are essential for the transmission to the mosquito vector. A vaccine targeting the sexual stages of the parasite and thus blocking transmission will be instrumental for the eradication of malaria. One of the leading transmission blocking vaccine candidates is the sexual stage antigen Pfs48/45. Areas covered: PubMed was searched to review the progress and future prospects for clinical development of a Pfs48/45-based subunit vaccine. We will focus on biological function, naturally acquired immunity, functional activity of specific antibodies, sequence diversity, production of recombinant protein and preclinical studies. Expert commentary: Pfs48/45 is one of the lead-candidates for a transmission blocking vaccine and should be further explored in clinical trials. |
| first_indexed | 2024-03-11T23:29:32Z |
| format | Article |
| id | doaj.art-290dfcc592604bb081428d909bb6073b |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:29:32Z |
| publishDate | 2017-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-290dfcc592604bb081428d909bb6073b2023-09-20T10:18:02ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952017-04-0116432933610.1080/14760584.2017.12768331276833Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccineMichael Theisen0Matthijs M. Jore1Robert Sauerwein2State Serum InstituteRadboud University Medical CenterRadboud University Medical CenterIntroduction: Malaria is a devastating vector-borne disease caused by the Plasmodium parasite, resulting in almost 0.5 million casualties per year. The parasite has a complex life-cycle that includes asexual replication in human red blood cells, causing symptomatic malaria, and sexual stages which are essential for the transmission to the mosquito vector. A vaccine targeting the sexual stages of the parasite and thus blocking transmission will be instrumental for the eradication of malaria. One of the leading transmission blocking vaccine candidates is the sexual stage antigen Pfs48/45. Areas covered: PubMed was searched to review the progress and future prospects for clinical development of a Pfs48/45-based subunit vaccine. We will focus on biological function, naturally acquired immunity, functional activity of specific antibodies, sequence diversity, production of recombinant protein and preclinical studies. Expert commentary: Pfs48/45 is one of the lead-candidates for a transmission blocking vaccine and should be further explored in clinical trials.http://dx.doi.org/10.1080/14760584.2017.1276833malariaplasmodium falciparumtransmission blocking vaccine (tbv)pfs48/45gametocytessubunit vaccine |
| spellingShingle | Michael Theisen Matthijs M. Jore Robert Sauerwein Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine Expert Review of Vaccines malaria plasmodium falciparum transmission blocking vaccine (tbv) pfs48/45 gametocytes subunit vaccine |
| title | Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine |
| title_full | Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine |
| title_fullStr | Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine |
| title_full_unstemmed | Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine |
| title_short | Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine |
| title_sort | towards clinical development of a pfs48 45 based transmission blocking malaria vaccine |
| topic | malaria plasmodium falciparum transmission blocking vaccine (tbv) pfs48/45 gametocytes subunit vaccine |
| url | http://dx.doi.org/10.1080/14760584.2017.1276833 |
| work_keys_str_mv | AT michaeltheisen towardsclinicaldevelopmentofapfs4845basedtransmissionblockingmalariavaccine AT matthijsmjore towardsclinicaldevelopmentofapfs4845basedtransmissionblockingmalariavaccine AT robertsauerwein towardsclinicaldevelopmentofapfs4845basedtransmissionblockingmalariavaccine |